YOUR SEARCH FOR Text 211 RESULTS
151 of Total
… SCHEDULE 13G CUSIP No. 1 Names of Reporting Persons The Vanguard Group 2 Check the …
152 of Total
Incyte Announces Executive Leadership Appointments | Incyte
… among its executive leadership team to support the Company’s strategic focus and long-term … our mutCALR antibody, povorcitinib, CDK2, KRAS G12D and TGFßR2xPD1 programs. Dr. Cagnoni has …
153 of Total
Culture & Careers | Incyte.com
… where problems get solved and lives are transformed. This isn’t your average … role in that.” Dija A. Clinical Operations 1/3 “We’re pushing the envelope as far as …
154 of Total
An Inclusive Environment | Incyte.com
… to develop and bring to market treatments for people living with diseases where there are … workplaces around the world. Since 2018, Incyte has been recognized as a top five …
156 of Total
From A Small Team of Research Scientists, Chemists & Biologists | Incyte.com
… November 20, 2022 Innovating for Tomorrow In 2002, a small group of research … are progressing a number of Phase 2 and Phase 3 clinical trials in a program called LIMBER. …
157 of Total
Financials | Incyte
… Annual Reports Quarterly Reports SEC Filings The … window) free of charge. 2024 Annual Report Form 10-K 1.5 MB Proxy 6.3 MB 2023 Annual Report Form …
158 of Total
Company Statements | Incyte.com
… Company Statements The information contained in company statements should … on Sun Pharmaceuticals, Inc. Litigation July 14, 2025 lncyte Celebrates the Recipients of the …
159 of Total
Events & Presentations | Incyte
… Events Corporate Presentations Scientific Presentations Date Title File Feb 10, 2026 Q4 2025 Financial and Corporate Update …
160 of Total
State Disclosures | Incyte.com
… State Disclosures Colorado Disclosure Act Colo. Rev. Stat. § 12-280-308 requires pharmaceutical …